Pharmaceutical Cannabis - D-A-CH

D-A-CH

Revenue in the Pharmaceutical Cannabis market in D-A-CH is forecasted to reach US$165.60m in 2024.
The revenue is anticipated to demonstrate an annual growth rate (CAGR 2024-2029) of 4.86%, leading to a market volume of US$209.90m by 2029.
When compared globally, the United States is expected to generate the highest revenue (US$913.10m in 2024).
In terms of per capita figures, US$3.04k in revenue is generated per person in 2024.
In D-A-CH, the Pharmaceutical Cannabis market is rapidly evolving, with Germany leading in research and Austria focusing on medical applications.

Key regions: United States, Spain, Europe, Thailand, Canada

Market

Region

Region comparison

Currency

Analyst Opinion

The Pharmaceutical Cannabis market in D-A-CH has been experiencing significant growth and development in recent years.

Customer preferences: Customers in the D-A-CH region are increasingly turning to Pharmaceutical Cannabis products due to the growing awareness of the potential health benefits associated with these products. The shift towards natural and alternative remedies has also influenced customer preferences in the Pharmaceutical Cannabis market.

Trends in the market: In Germany, there has been a noticeable trend towards the legalization and medical use of Cannabis products, including Pharmaceutical Cannabis. This trend is driven by changing regulations and an increasing acceptance of Cannabis for medical purposes. In Austria, the Pharmaceutical Cannabis market is also expanding, with more patients seeking Cannabis-based treatments for various health conditions. Switzerland, known for its progressive stance on Cannabis, has seen a rise in the production and export of Pharmaceutical Cannabis products.

Local special circumstances: Germany, as one of the largest pharmaceutical markets in Europe, plays a crucial role in shaping the Pharmaceutical Cannabis market in the D-A-CH region. The country's healthcare system and regulatory environment have a significant impact on the adoption and growth of Pharmaceutical Cannabis products. Austria, with its focus on research and innovation in healthcare, provides a supportive environment for the development of new Pharmaceutical Cannabis treatments. Switzerland's reputation for quality and precision in pharmaceutical manufacturing has positioned it as a key player in the Pharmaceutical Cannabis market.

Underlying macroeconomic factors: The growing acceptance and legalization of Cannabis for medical use across the D-A-CH region are driven by shifting attitudes towards healthcare and an increasing demand for alternative treatment options. Economic factors such as investment in research and development, healthcare infrastructure, and regulatory frameworks also play a crucial role in shaping the Pharmaceutical Cannabis market in D-A-CH.

Methodology

Data coverage:

Data encompasses B2B and B2C enterprises. Figures are based on companies' revenues, funding values and global consumer survey data. Revenues include retail, sales and taxes.

Modeling approach / Market size:

Market sizes are determined by a Top-Down approach, based on a specific rationale for each market market. As a basis for evaluating markets, we use financial reports, third-party data. Next, we use relevant key market indicators and data from country-specific associations such as tobacco spending per capita, medical product spending per capita, consumer spending and consumer spending for recreation purposes, population. This data helps us to estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, S-Curve function, ARIMA time series model and exponential curve function.

Additional Notes:

The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. GCS data is reweighted for representativeness.